Correlation Between Novo Nordisk and PDS Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and PDS Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and PDS Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novo Nordisk AS and PDS Biotechnology Corp, you can compare the effects of market volatilities on Novo Nordisk and PDS Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of PDS Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and PDS Biotechnology.

Diversification Opportunities for Novo Nordisk and PDS Biotechnology

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between Novo and PDS is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and PDS Biotechnology Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PDS Biotechnology Corp and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with PDS Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PDS Biotechnology Corp has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and PDS Biotechnology go up and down completely randomly.

Pair Corralation between Novo Nordisk and PDS Biotechnology

Assuming the 90 days trading horizon Novo Nordisk AS is expected to generate 0.72 times more return on investment than PDS Biotechnology. However, Novo Nordisk AS is 1.39 times less risky than PDS Biotechnology. It trades about -0.19 of its potential returns per unit of risk. PDS Biotechnology Corp is currently generating about -0.22 per unit of risk. If you would invest  8,520  in Novo Nordisk AS on October 25, 2024 and sell it today you would lose (820.00) from holding Novo Nordisk AS or give up 9.62% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Novo Nordisk AS  vs.  PDS Biotechnology Corp

 Performance 
       Timeline  
Novo Nordisk AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
PDS Biotechnology Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Novo Nordisk and PDS Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Novo Nordisk and PDS Biotechnology

The main advantage of trading using opposite Novo Nordisk and PDS Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, PDS Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PDS Biotechnology will offset losses from the drop in PDS Biotechnology's long position.
The idea behind Novo Nordisk AS and PDS Biotechnology Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals